Core Insights - Chicago Capital, LLC increased its stake in Procept BioRobotics by 999,873 shares, totaling 1,568,845 shares valued at $55.99 million as of quarter-end [1][2] - Procept BioRobotics' stock price was $34.61 as of October 21, 2025, reflecting a 48.57% decline year-over-year and underperforming the S&P 500 by 63.63 percentage points [2] - The company reported a revenue increase of 48% year-over-year in Q2, raising its full-year revenue outlook for 2025 to $325.5 million, a 45% increase over 2024 [9][10] Company Overview - Procept BioRobotics specializes in surgical robotics for urology, focusing on treating benign prostatic hyperplasia (BPH) with its AquaBeam Robotic System [4][5] - The company has a market capitalization of $1.95 billion and a trailing twelve months (TTM) revenue of $274.95 million, with a net income of -$84.15 million [3] Investment Rationale - Chicago Capital's significant increase in investment suggests confidence in Procept BioRobotics' growth potential despite recent stock price declines [7][11] - The company's rapid sales growth and attractive price-to-sales ratio of seven may indicate a compelling investment opportunity [10][11]

Core Viewpoint - PROCEPT BioRobotics has appointed Larry L. Wood as the new CEO, succeeding Reza Zadno, who has led the company to significant growth and expansion since 2020 [2][3]. Group 1: CEO Transition - Larry L. Wood, a seasoned executive with 18 years of experience at Edwards Lifesciences, will officially take over as CEO on September 2, 2025 [2][3]. - Under Zadno's leadership, PROCEPT achieved a substantial increase in annual surgical procedures from hundreds to nearly 100,000 for Aquablation therapy [4]. - The company completed an IPO in 2021, raising over $600 million [4]. Group 2: New CEO's Background - Wood has a strong background in the medical device industry, having served as Group President and Corporate Vice President at Edwards Lifesciences, where he was responsible for TAVR and structural heart disease operations [4][5]. - He has a proven track record of leading the development and commercialization of the SAPIEN transcatheter aortic valve replacement system, establishing TAVR as a global standard for aortic stenosis treatment [4][5]. - Wood's personal net worth is estimated at $16.21 million, primarily from his holdings in Edwards Lifesciences [5]. Group 3: Company Focus and Market Potential - PROCEPT BioRobotics specializes in robotic solutions for urology, with its core product, Aquablation Therapy, being the first ultrasound-guided, robot-assisted, non-thermal water ablation therapy for treating BPH [9][10]. - The company aims to expand the global market for Aquablation, with a 48% year-over-year revenue growth reported in Q2 2025 [11]. - PROCEPT has initiated clinical trials for prostate cancer treatment, indicating plans to broaden its product line to address more urological conditions [13]. Group 4: Strategic Advantages - Wood's experience in global commercialization and market entry strategies is expected to accelerate Aquablation's entry into new markets [13]. - His ability to navigate regulatory environments and secure reimbursement for new technologies may facilitate quicker adoption of BPH treatments in various countries [13]. - The company is developing a multi-procedure robotic platform, expanding its capabilities beyond BPH to include other urological diseases [13].